SURPASS Trials

  

                                                                            Tirzepatide 

Tirzepatide is a novel antidiabetic drug used for Type 2 Diabetes Mellitus and obesity, known for acting on two incretin receptors (GIP + GLP-1). It is one of the most important recent drugs in endocrinology.

• Developed by → Eli Lilly and Company 
• Brand names →
• Mounjaro (for diabetes)
• Zepbound (for obesity)

 

 

 

 

 

SURPASS

 

To Be Better 

 

 

 

 

 

 

SURPASS TRIAL 

 

The SURPASS clinical trial program is a series of global studies designed to test the efficacy and safety of tirzepatide, a dual GIP + GLP-1 receptor agonist, developed by Eli Lilly and Company 

Started: ~2018 

Participants: >13,000 patients worldwide

Focus: Glycemic control, weight loss, cardiovascular safety, and long-term outcomes. 

 

 

                                                 Tirzepatide: Effective In Weight Loss

 

 

 

 

Snapshot